The Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) group analyzed 12 pooled trials and concluded that the pathologic complete response (pCR) rates after NAC were also high in TNBC (33.6%), HER2-positive breast cancer (30.2%), grade 1/2 HR-positive breast cancer (7.5%), and grade 3 HR-positive breast cancer (16.2%) (3). This evidence concerns the gene ERBB2 and breast carcinoma.